LDL-ACT An actionable, decision support platform to predict LDL-C response to dietary restriction of animal products
- Coordinator
- Erevnitiko Kentro Vioiatrikon Epistimon Alexandros Flemingk, Greece
- Runs
- 1 November 2026 to 30 April 2028
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101334646
What the project is doing
In the project's own words, from its summary on CORDIS.
Cardiovascular disease (CVD) remains the leading cause of mortality worldwide, with elevated low-density lipoprotein cholesterol (LDL-C) representing a major causal, yet modifiable risk factor. Dietary restriction (DR) of animal products is widely recommended as a preventive strategy to lower LDL-C levels, however while some individuals experience clinically meaningful LDL-C reductions, others derive little benefit despite adherence.
This heterogeneity limits the effectiveness of current population-level dietary recommendations and highlights the need for more precise prevention strategies. The present proposal aims to address this variability and translate discoveries from the FastBio study into a data-driven, clinically actionable decision support platform that predicts individual LDL-C response to animal product DR. FastBio involves longitudinal multi-omic profiling of a unique population undergoing periodic DR of animal products, providing a rich resource for identifying predictors of dietary response.
The proposed platform will integrate anthropometric, biomarker, metabolic, gut microbiome, lifestyle and genetic factors to predict the magnitude of LDL-C reduction following DR and to stratify individuals according to their predicted response. It is intended as a practical decision support tool for clinicians and individuals, helping determine when dietary modification alone may be sufficient, and identifying those for whom it may delay or complement pharmacological treatment, while potentially improving adherence to preventive interventions.
The project will also explore IP protection, regulatory positioning and market feasibility, leading to a preliminary business plan and commercialisation roadmap. By shifting from population-level recommendations toward prediction of individual response to dietary intervention, this project addresses a key societal challenge and aims to advance precision prevention, enabling more effective strategies for reducing CVD risk.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Erevnitiko Kentro Vioiatrikon Epistimon Alexandros Flemingk | Vari-Athens | Greece | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI